The core activity of Calciscon AG is the development and distribution of in vitro diagnostic products, particularly in the field of Calcification Propensity (CPP) measurement, as well as the provision of measurement services for the examination of Calcification Propensity in blood, urine or other samples. The company focuses on the development of products for the diagnosis and monitoring of diseases such as kidney diseases and dementia.
AI-generated
Offering
Products & services
Industry:Medical Technology Industry
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
T50 blood test for measuring Calcification Propensity; identifies patients with elevated cardiovascular risk, supports therapy management and monitoring of treatment success.
Measurement service for Calcification Propensity
Measurement service for Calcification Propensity in blood, urine or other samples; analyses in Nidau, Switzerland, for clinical and scientific applications.
Measurement solution for T50 in accredited medical laboratories
Complete solution for T50 measurement for accredited medical laboratories; bundle consisting of the T50 test kit, reagents, external controls, pipette, optics and web software.
T50 measurement for clinical use
T50 measurement for CKD-5 and dialysis patients; for risk assessment, therapy adjustment and monitoring of the course in calcification-related cardiovascular events.